Beyond a synthetic lethal pair: The atorvastatin-gefitinib combination as a testable model for cross-pillar therapy in colorectal cancer

Abstract

We read with great interest the article by Huang and Ma which reported a synthetic lethal interaction between 3-hydroxy-3-methylglutaryl-CoA reductase and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta in colorectal cancer (CRC) using atorvastatin and gefitinib. This opinion review proposes an extended conceptual framework to interpret the synergy reported therein. We argue that this treatment may involve a cross-pillar interaction between sustained proliferative signaling, targeted by the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, and metabolic reprogramming, affected by cholesterol synthesis blockade through atorvastatin. This two-pronged pressure may limit the adaptive capacity of tumor cells and help explain the anti-proliferative and pro-autophagy effects reported. The AMP-activated protein kinase-sterol regulatory element-binding protein 1 node identified in the original study may serve as an integrative hub linking these pillars. Accumulating preclinical evidence from various cancers suggests that sterol regulatory element-binding protein family members can connect oncogenic signaling and metabolic adaptation. However, available data remain mainly from in vitro and xenograft models. This study may provide insight into a CRC-centered, testable cross-pillar framework rather than a broadly validated therapeutic paradigm. Future studies should assess patient-derived models, predictive biomarkers, safety, efficacy and the context-dependence of this strategy in CRC.

Keywords: Colorectal cancer; Synthetic lethality; Drug repurposing; Combination therapy; Cancer hallmarks; Sterol regulatory element-binding protein

Core Tip: The combination of atorvastatin and gefitinib may offer a colorectal cancer-centered cross-pillar therapeutic model that links complementary cancer hallmarks. A framework centered on sterol regulatory element-binding protein family members as integrative hubs linking oncogenic signaling to metabolic reprogramming may provide a mechanistic basis to rationalize the design of synergistic combination therapies. Although this testable model is currently supported mainly by preclinical evidence, it requires robust validation by multifactorial studies, patient-derived models, and biomarker-driven clinical trials.